As shown in Supplementary Fig. 7, treatment of trametinib resulted in effective downregulation of the RSK–EphA2 pathway; therefore, it is one possible strategy for intervention of phosphorylation of EphA2 for the treatment of cancers in a clinical context. Here, RPS6KA3 is linked to cancer.